(Q53217287)

12 May 2018

title

Molecular forms of somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with senile dementia of the Alzheimer type. (English)

1 reference

12 May 2018

0 references

1 reference

Strittmatter M

1

1 reference

12 May 2018

Cramer H

2

1 reference

12 May 2018

Reuner C

3

1 reference

12 May 2018

Strubel D

4

1 reference

12 May 2018

Hamann G

5

1 reference

12 May 2018

Schimrigk K

6

1 reference

12 May 2018

language of work or name

English

0 references

publication date

1 June 1997

1 reference

12 May 2018

published in

Biological Psychiatry

1 reference

12 May 2018

volume

41

1 reference

12 May 2018

issue

11

1 reference

12 May 2018

page(s)

1124-1130

1 reference

12 May 2018

Neurotransmitter changes in early- and late-onset Alzheimer-type dementia

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900211-9

Biogenic amines and their metabolites in Alzheimer's disease: noradrenaline, 5-hydroxytryptamine and 5-hydroxyindole-3-acetic acid depleted in hippocampus but not in substantia innominata.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900211-9

CSF somatostatin-like immunoreactivity in dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900211-9

Somatostatin in Alzheimer's disease and depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900211-9

Somatostatin immunoreactivity in cortical and some subcortical regions in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900211-9

Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900211-9

Somatostatin-like immunoreactivity and substance-P-like immunoreactivity in the CSF of patients with senile dementia of Alzheimer type, multi-infarct syndrome and communicating hydrocephalus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900211-9

A quantitative assessment of somatostatin-like and neuropeptide Y-like immunostained cells in the frontal and temporal cortex of patients with Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900211-9

Decreased somatostatin immunoreactivity but not neuropeptide Y immunoreactivity in cerebral cortex in senile dementia of Alzheimer type.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900211-9

Somatostatin messenger RNA-containing neurons in Alzheimer's disease: an in situ hybridization study in hippocampus, parahippocampal cortex and frontal cortex.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900211-9

Somatostatin and dementia in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900211-9

Subpopulations of somatostatin 28-immunoreactive neurons display different vulnerability in senile dementia of the Alzheimer type.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900211-9

Effects of haloperidol on somatostatin-like immunoreactivity in the CSF of Schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900211-9

Alzheimer's disease and senile dementia: biochemical characteristics and aspects of treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900211-9

Alterations in neuropeptides in aging and disease. Pathophysiology and potential for clinical intervention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900211-9

Neocortical concentrations of neuropeptides in senile dementia of the Alzheimer and Lewy body type: comparison with Parkinson's disease and severity correlations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900211-9

Aging, Alzheimer's disease, and the cholinergic system of the basal forebrain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900211-9

Somatostatin immunoreactivity in neuritic plaques of Alzheimer's patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900211-9

High-molecular-weight forms of somatostatin are reduced in Alzheimer's disease and Down's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900211-9

Serotonergic pathology is not widespread in Alzheimer patients without prominent aggressive symptoms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900211-9

Comparison between short- and long-term haloperidol administration on somatostatin and substance P concentrations in the rat brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900211-9

The Global Deterioration Scale for assessment of primary degenerative dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900211-9

Molecular size distribution of somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with degenerative brain disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900211-9

The Origin of Cerebrospinal Fluid Somatostatin: Hypothalamic or Disperse Central Nervous System Secretion?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900211-9

Reduced cholinesterase activity and somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with dementia of the Alzheimer type.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900211-9

Entorhinal cortex pathology in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900211-9

Metabolic half-life of somatostatin and peptidase activities are altered in Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900211-9

The basal forebrain cholinergic system: efferent and afferent connectivity and long-term effects of lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900211-9

inferred from DOI database lookup

7 January 2021

based on heuristic

Parkinson's disease and dementia: clinical and neurochemical correlations

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900211-9

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0006-3223(96)00211-9

1 reference

12 May 2018

1 reference

12 May 2018